Handman E, Noormohammadi A H, Curtis J M, Baldwin T, Sjölander A
The Walter and Eliza Hall Institute of Medical Research, Post Office Royal Melbourne Hospital, Victoria 3050, Australia.
Vaccine. 2000 Jul 1;18(26):3011-7. doi: 10.1016/s0264-410x(00)00109-2.
Prophylactic DNA vaccination protects mice against infection with Leishmania major by inducing an exclusive Th1 immune response dominated by the production of IFN-gamma. Here we show that DNA vaccines, initially designed to prevent infection, can also have a significant therapeutic effect. In L. major infected mice, vaccination with DNA encoding the Parasite Surface Antigen/gp46/M2 causes reduction in lesion size and promotes healing in both genetically resistant C3H/He mice and susceptible BALB/c mice. The therapeutic effect is underpinned by a shift in the T cell-derived cytokine environment with an increase in the IFN-gamma producing Th1 type cells. Application of such immunotherapy in conjunction with antiparasite drugs may result in faster or more certain cure of the disease in humans.
预防性DNA疫苗通过诱导以产生γ干扰素为主的特异性Th1免疫反应，保护小鼠免受硕大利什曼原虫感染。我们在此表明，最初设计用于预防感染的DNA疫苗也可具有显著的治疗效果。在感染硕大利什曼原虫的小鼠中，接种编码寄生虫表面抗原/gp46/M2的DNA疫苗可使病变大小减小，并促进基因抗性C3H/He小鼠和易感BALB/c小鼠的愈合。这种治疗效果的基础是T细胞衍生的细胞因子环境发生转变，产生γ干扰素的Th1型细胞增加。将这种免疫疗法与抗寄生虫药物联合应用可能会使人类疾病的治愈更快或更确定。
